Comparative Pharmacology
Head-to-head clinical analysis: SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE versus TRADJENTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE versus TRADJENTA.
SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE vs TRADJENTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and decreasing glucagon secretion. Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It slows the inactivation of incretin hormones GLP-1 and GIP, increasing their levels, which stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner.
Oral, 50 mg sitagliptin/500 mg metformin twice daily or 50 mg sitagliptin/1000 mg metformin twice daily, individually titrated based on glycemic response and tolerability. Maximum daily dose: sitagliptin 100 mg, metformin 2000 mg.
5 mg orally once daily.
None Documented
None Documented
Sitagliptin: 12.4 h; metformin: 6.2 h (prolonged in renal impairment).
Terminal elimination half-life is approximately 12.5 hours at steady state, consistent with once-daily dosing and supporting 24-hour DPP-4 inhibition.
Renal: sitagliptin ~87% unchanged in urine; metformin ~90% unchanged in urine. Biliary/fecal: minimal.
Approximately 85% of the dose is excreted in feces (mostly as unchanged parent drug) and about 5% in urine (largely as metabolites). Biliary excretion accounts for the majority of fecal elimination.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor